Practical Geriatrics ›› 2023, Vol. 37 ›› Issue (5): 528-531.doi: 10.3969/j.issn.1003-9198.2023.05.023
Previous Articles Next Articles
Received:2022-06-30
Online:2023-05-20
Published:2023-05-23
CLC Number:
| [1] COPPÉ J P, DESPREZ P Y, KRTOLICA A,et al. The senescence-associated secretory phenotype: the dark side of tumor suppression[J]. Annu Rev Pathol, 2010,5:99-118. [2] MYRIANTHOPOULOS V, EVANGELOU K, VASILEIOU P V S, et al.Senescence and senotherapeutics: a new field in cancer therapy[J]. Pharmacol Ther, 2019, 193:31-49. [3] THOMPSON PJ, SHAH A, NTRANOS V, et al. Targeted elimination of senescent beta cells prevents type 1 diabetes[J]. Cell Metab, 2019,29(5):1045-1060.e10. [4] AGUAYO-MAZZUCATO C, ANDLE J, LEE Jr T B, et al. Acceleration of β cell aging determines diabetes and senolysis improves disease outcomes[J]. Cell Metab, 2019,30(1):129-142.e4. [5] MUÑOZ-ESPÍN D, SERRANO M.Cellular senescence: from physiology to pathology[J]. Nat Rev Mol Cell Biol, 2014,15(7):482-496. [6] NGCOBO S R, NKAMBULE B B, NYAMBUYA T M, et al. Activated monocytes as a therapeutic target to attenuate vascular inflammation and lower cardiovascular disease-risk in patients with type 2 diabetes: a systematic review of preclinical and clinical studies[J]. Biomed Pharmacother, 2022,146:112579. [7] AL-MANSOORI L, AL-JABER H, PRINCE M S, et al. Role of inflammatory cytokines, growth factors and adipokines in adipogenesis and insulin resistance[J]. Inflammation, 2022,45(1):31-44. [8] CHYLIKOVA J, DVORACKOVA J, TAUBER Z, et al. M1/M2 macrophage polarization in human obese adipose tissue[J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2018, 162(2):79-82. [9] BALLAK D B, STIENSTRA R, TACK C J, et al. IL-1 family members in the pathogenesis and treatment of metabolic disease: focus on adipose tissue inflammation and insulin resistance[J]. Cytokine, 2015, 75(2):280-290. [10] ZATTERALE F, LONGO M, NADERI J, et al. Chronic adipose tissue inflammation linking obesity to insulin resistance and type 2 diabetes[J]. Front Physiol, 2020,10:1607. [11] ENGIN A B. Adipocyte-macrophage cross-talk in obesity[J]. Adv Exp Med Biol, 2017,960:327-343. [12] SINGH S, ANSHITA D, RAVICHANDIRAN V. MCP-1: function, regulation, and involvement in disease[J]. Int Immunopharmacol, 2021,101(Pt B):107598. [13] HUANG Y T, LIU C H, YANG Y C, et al. ROS- and HIF1α-dependent IGFBP3 upregulation blocks IGF1 survival signaling and thereby mediates high-glucose-induced cardiomyocyte apoptosis[J]. J Cell Physiol, 2019,234(8):13557-13570. [14] HAYWOOD N J, SLATER T A, MATTHEWS C J, et al. The insulin like growth factor and binding protein family: novel therapeutic targets in obesity & diabetes[J]. Mol Metab, 2019, 19:86-96. [15] HU B A, SAI W W, YUAN J, et al. PGF2α-FP receptor ameliorates senescence of VSMCs in vascular remodeling by Src/PAI-1 signal pathway[J]. Oxid Med Cell Longev, 2022.DOI: 10.1155/2022/2908261. [16] GUHA N, NEVITT S P, FRANCIS M, et al. The effects of recombinant human insulin-like growth factor-1/insulin-like growth factor binding protein-3 administration on lipid and carbohydrate metabolism in recreational athletes[J]. Clin Endocrinol: Oxf, 2021, 94(4):551-562. [17] ESPOSITO P, VERZOLA D, PICCIOTTO D, et al. Myostatin/activin-A signaling in the vessel wall and vascular calcification[J]. Cells, 2021,10(8):2070. [18] ROH J D, HOBSON R, CHAUDHARI V, et al. Activin type II receptor signaling in cardiac aging and heart failure[J]. Sci Transl Med, 2019,11(482):eaau8680. [19] CHANG S C, HSU C Y, LIU L K, et al. The association between serum activin A levels and albuminuria among community-dwelling middle-aged and older adults in Taiwan[J]. Sci Rep, 2021,11(1):20032. [20] BLUMENSATT M, GREULICH S, HERZFELD DE WIZA D, et al. Activin A impairs insulin action in cardiomyocytes via up-regulation of miR-143[J]. Cardiovasc Res, 2013,100(2):201-210. [21] UNGERLEIDER N A, BONOMI L M, BROWN M L, et al. Increased activin bioavailability enhances hepatic insulin sensitivity while inducing hepatic steatosis in male mice[J]. Endocrinology, 2013, 154(6):2025-2033. [22] WANG H L, WEI B, HE H J, et al. Smad3 deficiency improves islet-based therapy for diabetes and diabetic kidney injury by promoting β cell proliferationviathe E2F3-dependent mechanism[J]. Theranostics, 2022, 12(1):379-395. [23] CAO E, WATT M J, NOWELL C J, et al. Mesenteric lymphatic dysfunction promotes insulin resistance and represents a potential treatment target in obesity[J]. Nat Metab, 2021, 3(9):1175-1188. [24] INOUE H, HANAWA N, KATSUMATA-TSUBOI R, et al. Down-regulation of senescence marker protein 30 by iron-specific chelator deferoxamine drives cell senescence[J]. Biosci Biotechnol Biochem, 2018, 82(5):900-903. [25] JIN C, WU P, LI L,et al. Exosomes: emerging therapy delivery tools and biomarkers for kidney diseases[J]. Stem Cells Int, 2021.DOI: 10.1155/2021/7844455. [26] ZUBIRI I, POSADA-AYALA M, BENITO-MARTIN A, et al. Kidney tissue proteomics reveals regucalcin downregulation in response to diabetic nephropathy with reflection in urinary exosomes[J]. Transl Res, 2015, 166(5):474-484.e4. [27] ZHANG L, ZHU T, HE F, et al. Senescence marker protein 30(SMP30) protects against high glucose-induced apoptosis, oxidative stress and inflammatory response in retinal ganglion cells by enhancing Nrf2 activation via regulation of Akt/GSK-3β pathway[J]. Int Immunopharmacol, 2021,101(Pt B):108238. [28] ZHANG B, CUI S, BAI X, et al. SIRT3 overexpression antagonizes high glucose accelerated cellular senescence in human diploid fibroblasts via the SIRT3-FOXO1 signaling pathway[J]. Age: Dordr, 2013, 35(6):2237-2253. [29] D'MARCO L, MORILLO V, GORRIZ J L, et al. SGLT2i and GLP-1RA in cardiometabolic and renal diseases: from glycemic control to adipose tissue inflammation and senescence[J]. J Diabetes Res, 2021. DOI: 10.1155/2021/9032378. [30] WU W C, LEE W J, LEE T H, et al. Do different bariatric surgical procedures influence plasma levels of matrix metalloproteinase-2, -7, and -9 among patients with type 2 diabetes mellitus?[J]. World J Diabetes, 2020,11(6):252-260. [31] LÓPEZ-OTÍN C, BLASCO M A, PARTRIDGE L, et al. The hallmarks of aging[J]. Cell, 2013,153(6):1194-1217. [32] KHOSLA S, FARR J N, TCHKONIA T, et al. The role of cellular senescence in ageing and endocrine disease[J]. Nat Rev Endocrinol, 2020,16(5):263-275. [33] RUSSELL-JONES D, POUWER F, KHUNTI K. Identification of barriers to insulin therapy and approaches to overcoming them[J]. Diabetes Obes Metab, 2018, 20(3):488-496. |
| [1] | WANG Su, ZHAO Yijing, WEI Chenmin, CHEN Kun, CAO Wen, WANG Kun, YANG Yu. Correlation of triglyceride-glucose index with low-density lipoprotein subtypes in elderly patients with type 2 diabetes mellitus [J]. Practical Geriatrics, 2024, 38(10): 1002-1006. |
| [2] | GU Chonghuai, XIANG Xuejun, ZHENG Yuanxi, QIAO Rui, LIN Song. Efficacy of dapagliflozin in elderly patients undergoing coronary intervention with type 2 diabetes mellitus and ejection fraction reduced heart failure [J]. Practical Geriatrics, 2024, 38(10): 1025-1029. |
| [3] | . [J]. Practical Geriatrics, 2024, 38(10): 1066-1069. |
| [4] | LIU Qianhui, YAO Zijun, HE Yuli, XU Yunfan, WU Jun. Effects of HbA1c level on cardiac structure and function in elderly patients with type 2 diabetes mellitus and chronic heart failure [J]. Practical Geriatrics, 2024, 38(5): 491-437. |
| [5] | LIU Tongjun, ZHAO Yajie, HU Jieling, HU Yang, LIANG Wei. Effect of glucose metabolic disorders on serum levels of activin-A [J]. Practical Geriatrics, 2024, 38(5): 495-437. |
| [6] | . [J]. Practical Geriatrics, 2024, 38(5): 521-437. |
| [7] | . [J]. Practical Geriatrics, 2024, 38(5): 529-437. |
| [8] | TANG Yuan, DENG Shufang, HE Yongmei, DAI Yuxuan, LUO Jing. The status of health literacy and correlation with frailty in elderly patients with type 2 diabetes mellitus [J]. Practical Geriatrics, 2024, 38(3): 255-259. |
| [9] | DAI Ling-li, YU Yun. Association of estimated glomerular filtration rate with insulin resistance and β-cell function in elderly patients with type 2 diabetes mellitus [J]. Practical Geriatrics, 2023, 37(12): 1219-1223. |
| [10] | FAN Ting-yong, YUAN Li, YANG Xiao-ling, CHEN Qian. Assessment effect of Caprini scale on venous thromboembolism in elderly patients with diabetes [J]. Practical Geriatrics, 2023, 37(12): 1233-1237. |
| [11] | ZHANG He-cheng, WEI Su. Correlation of serum ferritin level with diabetic foot in elderly patients with type 2 diabetes mellitus [J]. Practical Geriatrics, 2023, 37(11): 1111-1114. |
| [12] | HU Yan, WU Hai-di, WANG Xue-fei, LOU Qing-lin, YE Qing, GU Liu-bao, DAI Jing, SONG Xiao-bo. Correlation between diabetic foot risk score and urinary microalbumin/creatinine ratio in elderly patients with type 2 diabetes [J]. Practical Geriatrics, 2023, 37(11): 1134-1137. |
| [13] | . [J]. Practical Geriatrics, 2023, 37(11): 1170-1175. |
| [14] | ZHANG Lin-ying, MEI Qun-chao, ZHANG Wei-qi, HU Yi-lan. Application of resistance training combined with high milk protein nutrition in elderly patients with type 2 diabetes mellitus and sarcopenia [J]. Practical Geriatrics, 2023, 37(10): 995-999. |
| [15] | . [J]. Practical Geriatrics, 2023, 37(10): 1064-1068. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
|
